MAP2K7 and breast carcinoma: Preclinical studies have demonstrated that the inhibition of MEK leads to the activation of the phosphatidylinositol 3-kinase (PI3K) pathway, a pathway that is also found to be deregulated in 30% of patients with basal-like breast cancer [84,118].